AZRX - AzurRx BioPharma, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.1000
-0.1200 (-9.84%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close1.2600
Open1.2200
Bid1.1100 x 2200
Ask1.1200 x 3000
Day's Range1.0150 - 1.3299
52 Week Range1.0000 - 3.7500
Volume679,130
Avg. Volume124,653
Market Cap23.166M
Beta (3Y Monthly)2.25
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Zacks Small Cap Research6 days ago

    AZRX: Launch of Study for Cystic Fibrosis Patients With Severe EPI

    The effort will examine combination use of MS1819-SD and pancreatic enzyme replacement therapy (PERT) for cystic fibrosis (CF) patients with severe exocrine pancreatic insufficiency (EPI). This is a subset of CF patients that are suffer from malnutrition and fail to absorb sufficient fat despite taking the maximum dose of PERT therapy. The new study will be conducted at six sites in Hungary with an enrollment target of 28.

  • How Many AzurRx BioPharma, Inc. (NASDAQ:AZRX) Shares Did Insiders Buy, In The Last Year?
    Simply Wall St.2 months ago

    How Many AzurRx BioPharma, Inc. (NASDAQ:AZRX) Shares Did Insiders Buy, In The Last Year?

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...

  • Zacks Small Cap Research2 months ago

    AZRX: Secondary Endpoint Data Released for MS1819-SD in Chronic Pancreatitis Patients

    On May 20th AzurRx BioPharma, Inc. (AZRX) presented secondary endpoint results for its Phase II Chronic Pancreatitis (CP) study, which completed clinical work in June 2018. The update follows topline and primary endpoint results released from the same trial last fall, which found a coefficient of fat absorption of 21.8% statistically significant to a p value of 0.002. The MS1819-SD Phase 2a open-label, dose escalation study was conducted in France, Australia and New Zealand.

  • Zacks Small Cap Research3 months ago

    AZRX: CF Study Up and Enrolling; Target to $8

    Highlights for the year and to date include participation in investment conferences, the addition of Dr. James Pennington as CMO, presentation of favorable trial data from chronic pancreatitis patients, the launch of the cystic fibrosis trial, and acquisition of rights from Protea and Mayoly. Research and development expenses were up 108% compared to the prior year period.

  • What Kind Of Shareholder Owns Most AzurRx BioPharma, Inc. (NASDAQ:AZRX) Stock?
    Simply Wall St.6 months ago

    What Kind Of Shareholder Owns Most AzurRx BioPharma, Inc. (NASDAQ:AZRX) Stock?

    If you want to know who really controls AzurRx BioPharma, Inc. (NASDAQ:AZRX), then you'll have to look at the makeup of its share registry. Generally speaking, as a company grows, Read More...

  • Zacks Small Cap Research7 months ago

    AZRX: 3Q:18 Financial and Operational Summary

    Highlights for the period and to date include participation in investment conferences, presentation of favorable trial data, acceptance of a new IND and a nod of approval from the Therapeutics Development Network for their cystic fibrosis trial protocol. Financial results for the quarter reflect the interim between the chronic pancreatitis study and the cystic fibrosis study and show an expected dip in cash burn. Research and development expenses were up 21% compared to the prior year period as AzurRx established its R&D function in the United States and recognized related costs, but were down sequentially, representing a break between the CP and CF studies.

  • Zacks Small Cap Research10 months ago

    AZRX: Final Results from Phase II EPI Trial

    Other endpoints were also positive, including Bristol stool scale, number of daily evacuations and weight of stool, which were consistent with the CFA results. CMO Dr. Pennington was pleased at the high level of statistical significance of the results and announced his expectation that the Phase IIb portion of the trial in cystic fibrosis (CF) will begin later in 2018. This compares to the dose response of just over 16% that was achieved in the Phase 1/2a FLIP110 study.

  • Zacks Small Cap Research11 months ago

    AZRX: Phase 2 Cystic Fibrosis Study to Start

    The company’s most important announcement year to date has been the completion of the Phase 2a trial for MS1819 in late June. Trial results were favorable and provided evidence of safety and efficacy for the Yarrowia lipolytica-derived lipase in exocrine pancreatic insufficiency (EPI). The company also raised $10 million in a public offering underwritten by Oppenheimer.